Jeffrey William Henderson insider trades

Open-market stock purchases and sales by Jeffrey William Henderson, Director at Halozyme Therapeutics, Inc, from SEC Form 4 filings since Feb 1, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -35%.

Recent trades

DateStockTradeValue
May 5, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
May 5, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Mar 17, 2026QCOM Qualcomm Inc/deBought (not open market)—
Mar 8, 2026QCOM Qualcomm Inc/deSold (not open market)$103K
Mar 8, 2026QCOM Qualcomm Inc/deBought (not open market)—
Mar 8, 2026QCOM Qualcomm Inc/deBought (not open market)—
Jan 27, 2026BDX Becton Dickinson & CoBought (not open market)—

Companies traded

  • HALO Halozyme Therapeutics, Inc: 11 sales, last May 5, 2026
  • QCOM Qualcomm Inc/de: 3 sales, last Mar 17, 2026
  • BDX Becton Dickinson & Co: 1 buy, last Jan 27, 2026
  • FGEN Fibrogen Inc: 5 sales, last Sep 1, 2023
  • CAH Cardinal Health Inc: 17 sales, last Aug 27, 2014

Get free alerts when Jeffrey William Henderson files a new trade →